Filtered By:
Specialty: Cardiology
Drug: Coumadin

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 1360 results found since Jan 2013.

Real-World Comparisons of Low-Dose NOACs versus Standard-Dose NOACs or Warfarin on Efficacy and Safety in Patients with AF: A Meta-Analysis
CONCLUSIONS: Low-dose NOACs were comparable to standard-dose NOACs considering risks of ischemic stroke, major bleeding, ICH, and GH, and they were superior to warfarin. Low-dose NOACs might be prescribed effectively and safely for patients with AF. Considering limitations, further well-designed prospective studies are foreseen.PMID:35449605 | PMC:PMC9017587 | DOI:10.1155/2022/4713826
Source: Cardiology Research and Practice - April 22, 2022 Category: Cardiology Authors: Ze Li Xiaozhen Wang Dandan Li Aiping Wen Source Type: research

Atrial Fibrillation in Heart Failure
This article explores the relationship between AF and HF and the thromboembolic effect of these diseases. Morbidity and mortality are increased when the 2 conditions are seen together. Stroke risks are significant with AF and all subtypes of HF. This article suggests that all patients with AF and HF should be considered for anticoagulation. Current evidence suggests that non –vitamin K antagonist oral anticoagulants are effective and safe in AF and HF in comparison with warfarin.
Source: Cardiology Clinics - April 22, 2022 Category: Cardiology Authors: Mohammed Obeidat, Malcolm Burgess, Gregory Y.H. Lip Source Type: research

Dolichoectasia: a brain arterial disease with an elusive treatment
We report four cases, all men 50 years or older. Of the two patients treated with doxycycline, we noted a slowdown of the basilar artery (BA) growth, but the BA continued to grow in the other patient. Of the two patients who received apixaban, none had a subsequent stroke in 5 and 4 years of follow-up, respectively. One patient was admitted with a fatal BA thrombosis and rupture, and pathological examination of the brain arteries demonstrated advanced arterial wall degeneration but no atherosclerosis.DISCUSSION: These cases exemplify the challenges of treating people with dolichoectasia and highlight the need for better ev...
Source: Atherosclerosis - April 20, 2022 Category: Cardiology Authors: Edgar R Lopez-Navarro Soojin Park Joshua Z Willey Jose Gutierrez Source Type: research

Trends of anticoagulant use and outcomes of patients with non-valvular atrial fibrillation: Findings from the RAFFINE registry
CONCLUSIONS: The all-cause mortality, cardiovascular mortality, and incidence of major bleeding events were higher in the warfarin group than in the DOAC group. After adjustment, warfarin use was not associated with an increase in these events. Off-label dosing of DOACs is not rare and is not associated with reduced effectiveness. The impact of off-label dosing of each DOAC on clinical events should be assessed using a larger population.PMID:35346556 | DOI:10.1016/j.jjcc.2022.03.006
Source: Journal of Cardiology - March 29, 2022 Category: Cardiology Authors: Sakiko Miyazaki Katsumi Miyauchi Hidemori Hayashi Kazuo Yamashiro Ryota Tanaka Yuji Nishizaki Shuko Nojiri Satoru Suwa Masataka Sumiyoshi Yuji Nakazato Takao Urabe Nobutaka Hattori Tohru Minamino Hiroyuki Daida Source Type: research

Safety and Effectiveness of Direct Oral Anticoagulants Versus Warfarin for Treating Left Ventricular Thrombus
ConclusionsIn this diverse population-based cohort of patients, DOAC treatment for left ventricular thrombus appears to be as safe and effective as warfarin treatment. These findings support the use of DOACs for patients with left ventricular thrombus.
Source: American Journal of Cardiovascular Drugs - March 29, 2022 Category: Cardiology Source Type: research

Comparison of the Efficacy and Safety of Non-vitamin K Antagonist Oral Anticoagulants with Warfarin in Atrial Fibrillation Patients with a History of Bleeding: A Systematic Review and Meta-Analysis
ConclusionsNOACs showed better efficacy and safety profile compared with warfarin in patients with AF and a history of bleeding. Randomized controlled trials are warranted to validate these findings.
Source: American Journal of Cardiovascular Drugs - March 16, 2022 Category: Cardiology Source Type: research

Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)
CONCLUSION: Statins are widely prescribed to patients with cardiovascular problems. Therefore, clinicians should pay attention to the patient's medical history, current prescribed doses, and drug interactions when adding new drugs or adjusting existing drugs.PMID:35242328 | PMC:PMC8861410 | DOI:10.1016/j.amsu.2022.103384
Source: Atherosclerosis - March 4, 2022 Category: Cardiology Authors: Saeed Kargar Soliemanabad Kimia Rasouli Zakaria Zakariaei Mostafa Soleymani Parastoo Karimi Aliabadi Source Type: research

Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
Conclusion In this nationwide cohort study of patients ≥75 years initiating oral anticoagulation for AF, standard and reduced dose NOACs were associated with similar risks of stroke/SE as warfarin and lower or similar risks of bleeding. The NOACs seem to be a safe option also in elderly patients.
Source: Heart - February 16, 2022 Category: Cardiology Authors: Rutherford, O.-C. W., Jonasson, C., Ghanima, W., Söderdahl, F., Halvorsen, S. Tags: Open access Arrhythmias and sudden death Source Type: research